Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals develops and commercializes therapeutics to treat non-viral, progressive liver diseases. The company's marketed product, obeticholic acid (OCA), has been approved in the U.S. for use in patients with primary biliary cholangitis, under the brand name Ocaliva?. OCA is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor. The company is also evaluating its development for OCA in other indications, including a variety of other non-viral progressive liver diseases such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.
  • TickerICPT
  • ISINUS45845P1084
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Liana Moussatos ...
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

Liana Moussatos ...
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Weekly Symphony Health Estimates for OCALIVA®

1 director sold

A director at Intercept Pharmaceuticals Inc sold 23,438 shares at 128.780USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

ValuEngine Rating and Forecast Report for ICPT

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in emerg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch